# Serina Therapeutics Inc. (SER)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $18M  
**Price:** $1.81 (+4.02%)

> Serina Therapeutics Inc., a biopharmaceutical company, focuses on the development of polymer-based therapeutics to address significant medical challenges. The company's primary innovation lies in its proprietary polyoxazoline (POZ) polymer technology, which is engineered to enhance the delivery and efficacy of pharmaceuticals. This novel platform aims to improve the pharmacokinetics and safety profiles of their drug candidates, making it a promising solution for patients with unmet medical needs. Serina Therapeutics operates within the biotechnology and pharmaceutical sectors, emphasizing the treatment of neurological diseases, cancer, and autoimmune conditions. The company's POZ technology has the potential to impact the drug delivery landscape, offering tailored solutions that prolong the drug's duration in the system and minimize side effects, thereby increasing therapeutic efficacy. In the competitive landscape of biopharmaceutical innovation, Serina Therapeutics Inc. plays a vital role by advancing the development of next-generation therapeutics that align with the evolving demands of precision medicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $130,000 | — | -$24M | -$19M | $-1.91 |
| 2024 | $56,000 | — | -$17M | -$11M | $-1.51 |
| 2023 | $3M | $102,000 | -$3M | $5M | $0.73 |
| 2022 | $34,000 | $21,000 | -$7M | -$10M | $-9.70 |
| 2021 | $144,000 | $125,000 | -$8M | -$9M | — |
| 2020 | $361,000 | $335,000 | -$10M | -$11M | — |
| 2019 | $2M | $1M | -$13M | -$12M | — |
| 2018 | $1M | $1M | -$11M | -$8M | — |
| 2017 | $1M | $1M | -$7M | -$7M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7M | $7M | -$37,000 | $3M | — |
| 2024 | $7M | $6M | $641,000 | $4M | — |
| 2023 | $9M | $5M | -$32M | $8M | — |
| 2022 | $3M | $21M | -$38M | $645,000 | $18M |
| 2021 | $3M | $15M | -$12M | $584,000 | $13M |
| 2020 | $4M | $9M | -$5M | $527,000 | — |
| 2019 | $7M | $5M | $2M | $2M | — |
| 2018 | $11M | $2M | $7M | $7M | — |
| 2017 | $10M | $1M | $7M | $7M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$18M | $59,000 | -$18M |
| 2024 | -$17M | $22,000 | -$17M |
| 2023 | -$2M | — | — |
| 2022 | -$6M | — | — |
| 2021 | -$8M | — | — |
| 2020 | -$8M | $20,000 | -$8M |
| 2019 | -$10M | $641,000 | -$11M |
| 2018 | -$8M | $21,000 | -$8M |
| 2017 | -$6M | $1,000 | -$6M |

Source: [CompaniesByCap](https://companiesbycap.com/company/SER)